Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to “Buy” Rating

Zoetis (NYSE:ZTS) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other analysts have also recently issued reports on ZTS. Bank of America increased their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. KeyCorp initiated coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Wednesday, December 3rd. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

NYSE:ZTS opened at $128.73 on Friday. The business’s fifty day moving average is $125.41 and its 200 day moving average is $134.80. The firm has a market cap of $54.34 billion, a price-to-earnings ratio of 21.38, a PEG ratio of 1.94 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis has a 52-week low of $115.25 and a 52-week high of $177.00.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the firm earned $1.40 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts predict that Zoetis will post 6.07 EPS for the current year.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently modified their holdings of the stock. North Star Asset Management Inc. increased its holdings in Zoetis by 4.9% in the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after buying an additional 67 shares in the last quarter. CVA Family Office LLC grew its stake in shares of Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after acquiring an additional 74 shares during the period. Bank of Nova Scotia Trust Co. raised its holdings in shares of Zoetis by 4.6% during the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock valued at $264,000 after purchasing an additional 74 shares during the last quarter. RWA Wealth Partners LLC lifted its position in Zoetis by 2.7% during the second quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock valued at $445,000 after purchasing an additional 76 shares during the period. Finally, Summit Place Financial Advisors LLC boosted its holdings in Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after purchasing an additional 76 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.